Reynders McVeigh Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,673
| Closed | -$283K | – | 197 |
|
|
2023
Q2 | $283K | Sell |
3,673
-282
| -7% | -$22.5K | 0.02% | 178 |
|
|
2023
Q1 | $328K | Buy |
3,955
+358
| +10% | +$29.7K | 0.02% | 164 |
|
|
2022
Q4 | $309K | Sell |
3,597
-171
| -5% | -$13.5K | 0.02% | 172 |
|
|
2022
Q3 | $232K | Buy |
3,768
+171
| +5% | +$10.8K | 0.02% | 193 |
|
|
2022
Q2 | $222K | Buy |
+3,597
| New | +$223K | 0.02% | 205 |
|
|
2022
Q1 | – | Sell |
-3,095
| Closed | -$225K | – | 236 |
|
|
2021
Q4 | $225K | Sell |
3,095
-644
| -17% | -$44.4K | 0.01% | 222 |
|
|
2021
Q3 | $261K | Buy |
3,739
+644
| +21% | +$45.2K | 0.02% | 201 |
|
|
2021
Q2 | $213K | Sell |
3,095
-4,005
| -56% | -$267K | 0.01% | 222 |
|
|
2021
Q1 | $459K | Sell |
7,100
-262
| -4% | -$16.9K | 0.03% | 162 |
|
|
2020
Q4 | $429K | Sell |
7,362
-4,240
| -37% | -$256K | 0.03% | 163 |
|
|
2020
Q3 | $733K | Sell |
11,602
-1,454
| -11% | -$101K | 0.06% | 121 |
|
|
2020
Q2 | $1M | Buy |
13,056
+1,459
| +13% | +$112K | 0.09% | 101 |
|
|
2020
Q1 | $867K | Sell |
11,597
-94
| -0.8% | -$6.5K | 0.1% | 99 |
|
|
2019
Q4 | $760K | Sell |
11,691
-1,025
| -8% | -$66.8K | 0.07% | 123 |
|
|
2019
Q3 | $806K | Sell |
12,716
-10
| -0.1% | -$654 | 0.09% | 113 |
|
|
2019
Q2 | $860K | Sell |
12,726
-1,008
| -7% | -$66.3K | 0.09% | 107 |
|
|
2019
Q1 | $893K | Sell |
13,734
-5,046
| -27% | -$335K | 0.1% | 107 |
|
|
2018
Q4 | $1.18M | Sell |
18,780
-18,277
| -49% | -$1.28M | 0.16% | 86 |
|
|
2018
Q3 | $2.86M | Sell |
37,057
-41,374
| -53% | -$3.12M | 0.34% | 60 |
|
|
2018
Q2 | $5.56M | Buy |
78,431
+2,701
| +4% | +$191K | 0.71% | 35 |
|
|
2018
Q1 | $5.71M | Buy |
75,730
+7,651
| +11% | +$608K | 0.72% | 35 |
|
|
2017
Q4 | $4.88M | Buy |
68,079
+19,800
| +41% | +$1.5M | 0.64% | 38 |
|
|
2017
Q3 | $3.91M | Sell |
48,279
-4,083
| -8% | -$312K | 0.51% | 41 |
|
|
2017
Q2 | $3.71M | Sell |
52,362
-30,736
| -37% | -$2.05M | 0.5% | 45 |
|
|
2017
Q1 | $5.64M | Sell |
83,098
-1,989
| -2% | -$140K | 0.78% | 36 |
|
|
2016
Q4 | $6.09M | Sell |
85,087
-13,318
| -14% | -$990K | 0.87% | 35 |
|
|
2016
Q3 | $7.79M | Buy |
98,405
+7,537
| +8% | +$612K | 1.13% | 25 |
|
|
2016
Q2 | $7.58M | Buy |
90,868
+41,001
| +82% | +$3.64M | 1.1% | 24 |
|
|
2016
Q1 | $4.58M | Buy |
49,867
+35,831
| +255% | +$3.23M | 0.68% | 36 |
|
|
2015
Q4 | $1.42M | Buy |
14,036
+2,566
| +22% | +$267K | 0.23% | 73 |
|
|
2015
Q3 | $1.13M | Hold |
11,470
| – | – | 0.2% | 82 |
|
|
2015
Q2 | $1.34M | Buy |
11,470
+230
| +2% | +$25.1K | 0.22% | 73 |
|
|
2015
Q1 | $1.1M | Buy |
11,240
+4,010
| +55% | +$407K | 0.19% | 79 |
|
|
2014
Q4 | $682K | Sell |
7,230
-490
| -6% | -$50.7K | 0.12% | 99 |
|
|
2014
Q3 | $822K | Sell |
7,720
-456
| -6% | -$44.7K | 0.16% | 85 |
|
|
2014
Q2 | $678K | Buy |
8,176
+170
| +2% | +$13.2K | 0.15% | 98 |
|
|
2014
Q1 | $567K | Sell |
8,006
-50
| -0.6% | -$3.92K | 0.13% | 103 |
|
|
2013
Q4 | $605K | Buy |
8,056
+50
| +0.6% | +$3.48K | 0.15% | 94 |
|
|
2013
Q3 | $503K | Sell |
8,006
-500
| -6% | -$29.9K | 0.14% | 104 |
|
|
2013
Q2 | $436K | Buy |
+8,506
| New | +$443K | 0.13% | 107 |
|
Other funds holding GILD
Reynders McVeigh Capital Management's GILD Position: Q3 2023 in Review
Reynders McVeigh Capital Management sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 3,673 shares — an estimated $283K sold.
Reynders McVeigh Capital Management first reported a position in GILD in Q2 2013 and held it in 40 quarters. The position peaked at $7.79M in Q3 2016. 1,682 funds tracked by Wall St. Rank hold GILD as of Q3 2023.
- Reynders McVeigh Capital Management reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
- Reynders McVeigh Capital Management sold 3,673 Gilead Sciences shares in Q3 2023, an estimated $283K.
- Reynders McVeigh Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 40 quarters.
- Reynders McVeigh Capital Management's Gilead Sciences position peaked at $7.79M in Q3 2016.
- 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.
Based on Reynders McVeigh Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.